Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
about
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosusDevelopment of paroxysmal nocturnal haemoglobinuria in systemic lupus erythematosus: an unusual cause of portal vein thrombosis.Metabolic alterations and increased liver mTOR expression precede the development of autoimmune disease in a murine model of lupus erythematosus.The role of aspirin in women's healthCardiovascular involvement in connective tissue disease: the role of interstitial lung diseaseRisk factors in cardiovascular disease in systemic lupus erythematosus.Short- and Long-term Outcomes in Patients with Connective Tissue Diseases Undergoing Percutaneous Coronary Intervention.New developments in lupus-associated antiphospholipid syndrome.Proximal aortic stiffness is increased in systemic lupus erythematosus activity in children and adolescents.Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.Current management of antiphospholipid syndrome-related thrombosis.Pathogenesis and treatment of atherosclerosis in lupus.Lactobacillus paracasei GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice.Characteristics and risk factors for hyperglycemia in Chinese female patients with systemic lupus erythematosus.Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus.
P2860
Q28072610-FD99B7F4-0C44-4832-9632-0878646F90A5Q33384872-B02E869D-B6A9-4CF0-8BB0-4158B6D182F9Q34506731-D5347889-03F9-4393-B8E6-9198371AA5CFQ35119642-8395EBF9-3273-4AD1-82EF-C57430324EBEQ35182436-D7474111-04AD-4566-A7FD-2F3DB298321AQ36644837-7AAFEDFD-D60D-4BE4-A464-3C8965DFE25BQ36760972-44226A46-45F6-46C3-A806-B7D4447446DFQ37168035-F41D785F-DDC7-42D2-98B8-98B0FED0B147Q37221927-FA90593E-EB77-4CFA-893F-3632F3DD0CF1Q37255201-C5CB0E66-7D59-4CC8-AEE2-FA12B7DC0306Q37425906-780F82ED-E8CA-43CE-BB4A-342AA18EB2F9Q37642830-B4DAA56D-28E3-4F65-8144-923B644CBACCQ38230699-29C5B946-6FDB-4341-8856-0B45FA299FEAQ42362111-783E3639-DFAB-4733-8C42-878E7A4ECF00Q42943405-0DD0C6BF-33F0-43E2-8D2E-EC591B4A1E8AQ44699349-50D8A001-CB7B-4DF2-AF42-1EA18C7B5D9DQ47260542-FC8E246B-6021-4CD7-8B4D-ECDB6AB49959
P2860
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@ast
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@en
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@nl
type
label
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@ast
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@en
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@nl
prefLabel
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@ast
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@en
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@nl
P2860
P356
P1476
Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
@en
P2093
Ian N Bruce
Sahena Haque
P2860
P2888
P304
P356
10.1038/NCPCARDIO0270
P407
P577
2005-08-01T00:00:00Z
P6179
1024093859